Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | HTR3A | P46098 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249587 | 0.92 | HRH3 (0.46) | HRH3KCNH2ADRA1A | |
| SCHEMBL10249721 | 0.90 | RAB9A (0.40) | HRH3KCNH2ADRA1AESR1HRH1 | |
| SCHEMBL12334400 | 0.86 | HRH3 (0.51) | HRH3KCNH2ADRA1AESR1HRH1 | |
| SCHEMBL10097367 | 0.84 | HRH3 (0.44) | HRH3KCNH2ADRA1AHRH1HTR3A | |
| SCHEMBL10097289 | 0.84 | HRH3 (0.48) | HRH3KCNH2ADRA1AESR1 | |
| SCHEMBL13151973 | 0.84 | HRH3 (0.43) | HRH3KCNH2ADRA1AHTR3A | |
| SCHEMBL10097292 | 0.83 | HRH3 (0.46) | HRH3KCNH2ADRA1AESR1 | |
| SCHEMBL13152603 | 0.82 | MAPT (0.44) | MAOB | |
| SCHEMBL13151837 | 0.82 | GRIK2 (0.41) | MAOB | |
| SCHEMBL13152111 | 0.82 | GRIK2 (0.38) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | HRH3 976/4885KCNH2 3873/4885ADRA1A 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.